Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
With
Worldwide Clinical Trials
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18-75 years old
Diagnosed with B-NHL
Relapsed after or be refractory to at least 2 line of standard therapy
You may not be if
Active central nervous system (CNS) metastases
Positive Direct Antiglobulin Test (DAT)
Active autoimmune disorder
Skin disorders that do not requires hormone replacement therapy
Clareo Health | Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)
